The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

Bibliographic Details
Title: The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Authors: Daniela Dudysová, Karolina Janků, Michal Šmotek, Elizaveta Saifutdinova, Jana Kopřivová, Jitka Bušková, Bryce Anthony Mander, Martin Brunovský, Peter Zach, Jakub Korčák, Veronika Andrashko, Michaela Viktorinová, Filip Tylš, Anna Bravermanová, Tom Froese, Tomáš Páleníček, Jiří Horáček
Source: Frontiers in Pharmacology, Vol 11 (2020)
Publisher Information: Frontiers Media S.A., 2020.
Publication Year: 2020
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: neuroplasticity, EEG power spectra, antidepressant, psilocybin, sleep, Rapid Eye Movement sleep, Therapeutics. Pharmacology, RM1-950
More Details: Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we hypothesized that psilocybin, similar to other classical antidepressants, would reduce rapid eye movement (REM) sleep and prolong REM sleep latency. Moreover, we also hypothesized that psilocybin would promote slow-wave activity (SWA) expression in the first sleep cycle, a marker of sleep-related neuroplasticity. Twenty healthy volunteers (10 women, age 28–53) underwent two drug administration sessions, psilocybin or placebo, in a randomized, double-blinded design. Changes in sleep macrostructure, SWA during the first sleep cycle, whole night EEG spectral power across frequencies in non-rapid eye movement (NREM) and REM sleep, and changes in subjective sleep measures were analyzed. The results revealed prolonged REM sleep latency after psilocybin administration and a trend toward a decrease in overall REM sleep duration. No changes in NREM sleep were observed. Psilocybin did not affect EEG power spectra in NREM or REM sleep when examined across the whole night. However, psilocybin suppressed SWA in the first sleep cycle. No evidence was found for sleep-related neuroplasticity, however, a different dosage, timing, effect on homeostatic regulation of sleep, or other mechanisms related to antidepressant effects may play a role. Overall, this study suggests that potential antidepressant properties of psilocybin might be related to changes in sleep.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2020.602590/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2020.602590
Access URL: https://doaj.org/article/2c60ad15328a4bd09f38d9d502c6a964
Accession Number: edsdoj.2c60ad15328a4bd09f38d9d502c6a964
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2020.602590
Published in:Frontiers in Pharmacology
Language:English